Metabolic syndrome components and risk factors for pancreatic adenocarcinoma: A case-control study in China

Digestion

Volumn 86, Issue 4, 2013, Pages 294-301

  Wu, Qiao ^a   Chen, Ge ^a   Wu, Wen Ming ^a   Zhou, Li ^a   You, Lei ^a   Zhang, Tai Ping ^a   Zhao, Yu Pei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Metabolic syndrome; Pancreatic adenocarcinoma; Risk factors

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; CHOLESTEROL; GLUCOSE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CASE CONTROL STUDY; CHINA; CHOLECYSTECTOMY; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CHRONIC PANCREATITIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METABOLIC SYNDROME X; PANCREAS ADENOCARCINOMA; PANCREAS DISEASE; PRIORITY JOURNAL; RISK FACTOR; SMOKING;

ADENOCARCINOMA; AGED; APOLIPOPROTEINS A; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHINA; CHOLECYSTOLITHIASIS; CHOLESTEROL; CONFIDENCE INTERVALS; DIABETES MELLITUS; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; RISK FACTORS; SMOKING;

EID: 84867685636     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000341397     Document Type: Article

References (65)

1. Perrin MC, Terry MB, Kleinhaus K, Deutsch L, Yanetz R, Tiram E, Calderon R, Friedlander Y, Paltiel O, Harlap S: Gestational diabetes as a risk factor for pancreatic cancer: A prospective cohort study. BMC Med 2007; 5: 25.
2. Stoita A, Penman ID, Williams DB: Review of screening for pancreatic cancer in highrisk individuals. World J Gastroenterol 2011; 17: 2365-2371.
3. Permuth-Wey J, Egan KM: Family history is a significant risk factor for pancreatic cancer: Results from a systematic review and meta-analysis. Fam Cancer 2009; 8: 109-117.
4. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, Dooley WC, Coleman J, Pitt HA: Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995; 221: 721-731.
5. Brand RE, Lynch HT: Hereditary pancreatic adenocarcinoma. A clinical perspective. Med Clin North Am 2000; 84: 665-675.
6. Kornmann M, Beger HG, Korc M: Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas 1998; 17: 169-175.
7. Lukic S, Nikolic A, Alempijevic T, Popovic D, Sokic Milutinovic A, Ugljesic M, Knezevic S, Milicic B, Dinic D, Radojkovic D: Angiotensin-converting enzyme gene insertion/deletion polymorphism in patients with chronic pancreatitis and pancreatic cancer. Dig Surg 2011; 28: 258-262.
8. Coughlin SS, Calle EE, Patel AV, Thun MJ: Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 2000; 11: 915-923.
9. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB: Tobacco and the risk of pancreatic cancer: A review and meta-analysis. Langenbecks Arch Surg 2008; 393: 535-545.
10. Gapstur SM, Jacobs EJ, Deka A, McCullough ML, Patel AV, Thun MJ: Association of alcohol intake with pancreatic cancer mortality in never smokers. Arch Intern Med 2011; 171: 444-451.
11. Hassan MM, Bondy ML, Wolff RA, Abbruzzese JL, Vauthey JN, Pisters PW, Evans DB, Khan R, Chou TH, Lenzi R, Jiao L, Li D: Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol 2007; 102: 2696-2707.
12. Raimondi S, Maisonneuve P, Lowenfels AB: Epidemiology of pancreatic cancer: An overview. Nat Rev Gastroenterol Hepatol 2009; 6: 699-708.
13. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M: Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076-2083.
14. Everhart J, Wright D: Diabetes mellitus as a risk factor for pancreatic cancer. A metaanalysis. JAMA 1995; 273: 1605-1609.
15. Eberle CA, Bracci PM, Holly EA: Anthropometric factors and pancreatic cancer in a population-based case-control study in the San Francisco Bay area. Cancer Causes Control 2005; 16: 1235-1244.
16. Larsson SC, Permert J, Hakansson N, Naslund I, Bergkvist L, Wolk A: Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish populationbased cohorts. Br J Cancer 2005; 93: 1310-1315.
17. Larsson SC, Orsini N, Wolk A: Body mass index and pancreatic cancer risk: A metaanalysis of prospective studies. Int J Cancer 2007; 120: 1993-1998.
18. Lee MY, Lin KD, Hsiao PJ, Shin SJ: The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients. Metabolism 2012; 61: 242-249.
19. Lipworth L, Zucchetto A, Bosetti C, Franceschi S, Talamini R, Serraino D, McLaughlin JK, La Vecchia C, Negri E: Diabetes mellitus, other medical conditions and pancreatic cancer: A case-control study. Diabetes Metab Res Rev 2011; 27: 255-261.
20. Wang F, Herrington M, Larsson J, Permert J: The relationship between diabetes and pancreatic cancer. Mol Cancer 2003; 2: 4.
21. Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A: Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000; 283: 2552-2558.
22. Suzuki H, Li Y, Dong X, Hassan MM, Abbruzzese JL, Li D: Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 3467-3473.
23. Hennig R, Ding XZ, Adrian TE: On the role of the islets of Langerhans in pancreatic cancer. Histol Histopathol 2004; 19: 999-1011.
24. Fisher WE, Boros LG, Schirmer WJ: Insulin promotes pancreatic cancer: Evidence for endocrine influence on exocrine pancreatic tumors. J Surg Res 1996; 63: 310-313.
25. Ding XZ, Fehsenfeld DM, Murphy LO, Permert J, Adrian TE: Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas 2000; 21: 310-320.
26. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C: Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007; 121: 2381-2386.
27. Ohshima H, Tatemichi M, Sawa T: Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys 2003; 417: 3-11.
28. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S: Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev Res (Phila) 2010; 3: 1451-1461.
29. Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, Koide T, Tokoro C, Abe Y, Inamori M, Nakagama H, Nakajima A: Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 2010; 3: 1077-1083.
30. Pollak M: Metformin and other biguanides in oncology: Advancing the research agenda. Cancer Prev Res (Phila) 2010; 3: 1060-1065.
31. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC: Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: A population-based cohort study. Am J Gastroenterol 2012; 107: 46-52.
32. Bowker SL, Majumdar SR, Veugelers P, Johnson JA: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-258.
33. Giovannucci E: Insulin, insulin-like growth factors and colon cancer: A review of the evidence. J Nutr 2001; 131: 3109SY3120S.
34. Furberg AS, Veierod MB, Wilsgaard T, Bernstein L, Thune I: Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst 2004; 96: 1152-1160.
35. Michalaki V, Koutroulis G, Syrigos K, Piperi C, Kalofoutis A: Evaluation of serum lipids and high-density lipoprotein subfractions (HDL2, HDL3) in postmenopausal patients with breast cancer. Mol Cell Biochem 2005; 268: 19-24.
36. Hammarsten J, Hogstedt B: Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 2004; 13: 47-55.
37. Feingold KR, Soued M, Adi S, Staprans I, Shigenaga J, Doerrler W, Moser A, Grunfeld C: Tumor necrosis factor-increased hepatic very-low-density lipoprotein production and increased serum triglyceride levels in diabetic rats. Diabetes 1990; 39: 1569-1574.
38. Hardardottir I, Grunfeld C, Feingold KR: Effects of endotoxin and cytokines on lipid metabolism. Curr Opin Lipidol 1994; 5: 207-215.
39. Oh HY, Lee EJ, Yoon S, Chung BH, Cho KS, Hong SJ: Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction. Prostate 2007; 67: 1061-1069.
40. Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR: Cholesterol-rich lipid rafts mediate Akt-regulated survival in prostate cancer cells. Cancer Res 2002; 62: 2227-2231.
41. Van Hemelrijck M, Walldius G, Jungner I, Hammar N, Garmo H, Binda E, Hayday A, Lambe M, Holmberg L: Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes Control 2011; 22: 1011-1019.
42. Calabresi L, Rossoni G, Gomaraschi M, Sisto F, Berti F, Franceschini G: High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor- content and enhancing prostaglandin release. Circ Res 2003; 92: 330-337.
43. Han C, Zhang HT, Du L, Liu X, Jing J, Zhao X, Yang X, Tian B: Serum levels of leptin, insulin, and lipids in relation to breast cancer in china. Endocrine 2005; 26: 19-24.
44. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW: Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64: 5882-5890.
45. Maisonneuve P, Lowenfels AB, Bueno-de-Mesquita HB, Ghadirian P, Baghurst PA, Zatonski WA, Miller AB, Duell EJ, Boffetta P, Boyle P: Past medical history and pancreatic cancer risk: Results from a multicenter casecontrol study. Ann Epidemiol 2010; 20: 92-98.
46. Bracci PM, Wang F, Hassan MM, Gupta S, Li D, Holly EA: Pancreatitis and pancreatic cancer in two large pooled case-control studies. Cancer Causes Control 2009; 20: 1723-1731.
47. Nitsche C, Simon P, Weiss FU, Fluhr G, Weber E, Gartner S, Behn CO, Kraft M, Ringel J, Aghdassi A, Mayerle J, Lerch MM: Environmental risk factors for chronic pancreatitis and pancreatic cancer. Dig Dis 2011; 29: 235-242.
48. Lohr M, Kloppel G, Maisonneuve P, Lowenfels AB, Luttges J: Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: A metaanalysis. Neoplasia 2005; 7: 17-23.
49. Yanagisawa A, Ohtake K, Ohashi K, Hori M, Kitagawa T, Sugano H, Kato Y: Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 1993; 53: 953-956.
50. Rivera JA, Rall CJ, Graeme-Cook F, Fernandezdel Castillo C, Shu P, Lakey N, Tepper R, Rattner DW, Warshaw AL, Rustgi AK: Analysis of K-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia. Surgery 1997; 121: 42-49.
51. Ji B, Tsou L, Wang H, Gaiser S, Chang DZ, Daniluk J, Bi Y, Grote T, Longnecker DS, Logsdon CD: Ras activity levels control the development of pancreatic diseases. Gastroenterology 2009; 137: 1072-1082.e6.
52. Thomsen RW, Thomsen HF, Norgaard M, Cetin K, McLaughlin JK, Tarone RE, Fryzek JP, Sorensen HT: Risk of cholecystitis in patients with cancer: A population-based cohort study in Denmark. Cancer 2008; 113: 3410-3419.
53. Silverman DT, Schiffman M, Everhart J, Goldstein A, Lillemoe KD, Swanson GM, Schwartz AG, Brown LM, Greenberg RS, Schoenberg JB, Pottern LM, Hoover RN, Fraumeni JF Jr: Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999; 80: 1830-1837.
54. Wang DS, Chen DL, Ren C, Wang ZQ, Qiu MZ, Luo HY, Zhang DS, Wang FH, Li YH, Xu RH: Abo blood group, hepatitis B viral infection, and risk of pancreatic cancer. Int J Cancer 2012; 131: 461-468.
55. Hardt PD, Bretz L, Krauss A, Schnell-Kretschmer H, Wusten O, Nalop J, Zekorn T, Klor HU: Pathological pancreatic exocrine function and duct morphology in patients with cholelithiasis. Dig Dis Sci 2001; 46: 536-539.
56. Olsen TS: The incidence and clinical relevance of chronic inflammation in the pancreas in autopsy material. Acta Pathol Microbiol Scand A 1978; 86A:361-365.
57. Doerr W: Pathogenesis of acute and chronic pancreatitis (in German). Verh Dtsch Ges Inn Med 1964; 70: 718-758.
58. Ye W, Lagergren J, Nyren O, Ekbom A: Risk of pancreatic cancer after cholecystectomy: A cohort study in Sweden. Gut 2001; 49: 678-681.
59. Ekbom A, Yuen J, Karlsson BM, McLaughlin JK, Adami HO: Risk of pancreatic and periampullar cancer following cholecystectomy: A population-based cohort study. Dig Dis Sci 1996; 41: 387-391.
60. Shibata A, Mack TM, Paganini-Hill A, Ross RK, Henderson BE: A prospective study of pancreatic cancer in the elderly. Int J Cancer 1994; 58: 46-49.
61. Haddock G, Carter DC: Aetiology of pancreatic cancer. Br J Surg 1990; 77: 1159-1166.
62. Smith JP, Solomon TE, Bagheri S, Kramer S: Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990. Dig Dis Sci 1990; 35: 1377-1384.
63. Axelson J, Ihse I, Hakanson R: Pancreatic cancer: The role of cholecystokinin? Scand J Gastroenterol 1992; 27: 993-998.
64. Fuchs CS, Colditz GA, Stampfer MJ, Giovannucci EL, Hunter DJ, Rimm EB, Willett WC, Speizer FE: A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med 1996; 156: 2255-2260.
65. Nilsen TI, Vatten LJ: A prospective study of lifestyle factors and the risk of pancreatic cancer in Nord-Trondelag, Norway. Cancer Causes Control 2000; 11: 645-652.